Research programme: dendrimer-based proteins and monoclonal antibodies - Starpharma

Drug Profile

Research programme: dendrimer-based proteins and monoclonal antibodies - Starpharma

Alternative Names: ADME Engineering; Dendrimer-antibodies; Dendrimer-monoclonal antibody formulations - Starpharma; Dendrimer-protein formulations - Starpharma; Dendrimer-proteins

Latest Information Update: 08 May 2012

Price : $50

At a glance

  • Originator Starpharma
  • Class Dendrimers; Monoclonal antibodies; Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Unspecified

Most Recent Events

  • 19 Dec 2011 Starpharma and Eli Lilly expand their development collaboration; preclinical development is ongoing
  • 29 Feb 2008 Early research in Undefined indication in Australia (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top